Studies evaluating the efficacy and safety of the fixed-dose combination ledipasvir (LDV)/ sofosbuvir (SOF) in patients coinfected with HIV-1 and hepatitis C virus (HCV) have mainly included treatment-na€ ıve patients without cirrhosis. We aimed to evaluate the efficacy and safety of this combination in treatment-experienced patients with and without cirrhosis.
Introduction
To date, most of the studies evaluating the efficacy and safety of the fixed-dose combination of ledipasvir [LDV; an inhibitor of nonstructural protein 5A (NS5A)] and sofosbuvir (SOF; a nucleotide NS5B polymerase inhibitor) in patients coinfected with HIV-1 and hepatitis C virus (HCV) have mainly included individuals without cirrhosis and with no previous exposure to direct-acting antiviral agents (DAAs). Overall, these studies showed high rates of sustained virological response (SVR) in HIV/HCV-coinfected patients with genotype 1 or 4 [1, 2] . The phase 2 ERADICATE study showed that, after 12 weeks of LDV/SOF in 50 treatment-na€ ıve, noncirrhotic patients coinfected with HCV genotype 1 and HIV-1, the rate of SVR 12 weeks after the end of the therapy (SVR12) was 98% [1] . The ION-4 phase 3 study evaluated the single fixed-dose combination for 12 weeks in 335 HIV-seropositive patients with both HCV genotype 1 and genotype 4 coinfections, including 185 HCV treatment-experienced individuals (53 patients exposed to NS3/4A PIs) and 67 patients with cirrhosis. Overall, this study showed a 96.1% response rate in terms of SVR12 (96.6% vs. 94.0% in noncirrhotic and cirrhotic patients, respectively; difference not significant) [2] . These studies also showed that LDV/SOF in HIV/ HCV-coinfected patients produced a similar SVR rate to that in HCV-monoinfected patients [3] . Nevertheless, relative to HCV-monoinfected patients, drug interactions with antiretrovirals may complicate treatment of coinfected patients and expose them to secondary events, particularly in patients with cirrhosis.
The SOFTRIH study aimed to evaluate the efficacy, safety and patient-reported outcomes (PROs) of combined treatment with LDV/SOF in a population of patients coinfected with HIV-1 and HCV genotype 1 who had virological failure on or were intolerant to NS3/4A protease inhibitors (PIs), including subjects with compensated cirrhosis.
Methods

Study design and setting
This study was a nonrandomized, double-arm, open-label phase II pilot trial conducted between August 2014 and December 2015 in 30 French centres. The sponsor [Inserm-Agence Nationale de Recherche sur le Sida et les H epatites Virales (ANRS)] designed and conducted the study, and collected, monitored and analysed the data. Study drugs were kindly provided by Gilead Sciences, Inc. (Foster City, CA, USA). The study protocol (EUDRACT number 2013-002607-33) was approved by Ethical Committee CPP-Sud-M editerran ee-1 (Marseille, France) and by the French Regulatory Authority Agence nationale de s ecurit e du m edicament et des produits de sant e (ANSM) (Saint-Denis, France). It was registered in the ClinicalTrials.gov database under reference NCT02125500. The study was conducted in compliance with the Declaration of Helsinki and Good Clinical Practice Guidelines and regulatory requirements. All participants provided written informed consent.
Patients
Patients enrolled in the study had to be HIV/HCV genotype 1-coinfected adults, with a screening level of HCV RNA of at least 1000 IU/mL. Other inclusion criteria were: virological failure or premature discontinuation for intolerance of a previous triple therapy with pegylated (peg)-interferon/ribavirin and a first-generation PI; previous anti-HCV treatment interrupted for at least 3 months; stable antiretroviral treatment (combination of permitted molecules: tenofovir, emtricitabine, lamivudine, efavirenz, raltegravir, rilpivirine and enfuvirtide; as insufficient data on drug-drug interactions with LDV were available at this time, dolutegravir was not allowed) for at least 4 weeks before screening; HIV RNA < 50 HIV-1 RNA copies/mL for at least 3 months; CD4 count of > 100 cells/lL and CD4 percentage > 15%. The main noninclusion criteria were Child-Pugh B or C cirrhosis or a history of cirrhosis decompensation, coinfection with hepatitis B virus and any organ transplantation. As a result of the interaction between LDV and tenofovir leading to an increase in tenofovir exposure, a minimum creatinine clearance of 60 mL/ min, as calculated with the Modification of Diet in Renal Disease (MDRD) formula, was required for enrolment. Full eligibility criteria are given in the Appendix S1. Fibrosis was evaluated at screening in all patients with the assessment of the presence or absence of cirrhosis based on:
• previous liver biopsy exhibiting cirrhotic lesions, • and/or significant liver biopsy (cumulative length ≥ 15 mm or ≥ 5 portal spaces) within the past 18 months,
• and/or significant and reliable liver stiffness assessment (Fibroscanâ, Echosens, Paris, France) within the past 6 months [at least 10 measures with interquartile range (IQR) < 30% of the median value and a success rate of ≥ 70%].
Cirrhosis was defined as a METAVIR score of F4 on the liver puncture biopsy and/or hepatic impulse elastometry ≥ 14.5 kPa.
Procedures
Cirrhotic patients received 24 weeks of the LDV/SOF (90/ 400 mg) fixed-dose combination once daily. Noncirrhotic patients received the same regimen for 12 weeks. The study treatment had to be interrupted in the case of: (1) virological failure, defined as a confirmed breakthrough (an increase from nonquantifiable to quantifiable HCV RNA or to ≥ 1 log 10 IU/mL above nadir); (2) intolerance, defined as a confirmed increase of alanine aminotransferase (ALT) to 5 times the nadir and ALT > upper limit of normal.
Outcomes and measurements
The primary efficacy endpoint was an SVR12 (undetectable HCV RNA). Key secondary efficacy endpoints were SVR4, SVR24 and virological response measured at weeks 1, 2, 4, 12, 16, 20, 24, 30, 36, and 42 plus week 48 in cirrhotic patients. Plasma HCV RNA levels were quantified in virology laboratories local to the sites using one of the following techniques: the COBAS AmpliPrep/ COBAS TaqMan HCV test, version 2.0 (Roche Molecular Systems, Pleasanton, CA, USA) with a lower limit of quantification (LLOQ) of 15 IU/mL or the Abbott RealTime HCV Assay (Abbott Molecular, Des Plaines, IL, USA) with an LLOQ of 12 IU/mL.
Safety endpoints included the frequency and severity of adverse events, discontinuations of study treatment and safety laboratory changes (including HIV virological assessment). All study participants were monitored frequently for adverse events and clinical laboratory results were recorded throughout the study. Adverse events were graded by investigators according to the Inserm-ANRS Scale for Scoring of Adverse Events Seriousness (v6; 9 September 2003). HIV RNA was measured with the Abbott RealTime HIV-1 Assay (Abbott Molecular) or the COBAS AmpliPrep/COBAS TaqMan-HIV Test, version 2 (Roche Molecular Systems). HIV viral load (VL) was considered detectable if > 50 copies/mL. HIV virological failure was defined as at least one HIV VL over this threshold, confirmed within 2 weeks.
Moreover, repeated assessments of PROs were scheduled throughout the follow-up, including assessments of adherence to HIV and HCV treatments (using the Inserm-ANRS self-administered questionnaire [4] ), self-reported symptoms [using the ANRS AC24 questionnaire derived from the AIDS Clinical Trials Group (ACTG) Symptom Distress Module [5] ] as indicators of patients' subjective experience with treatments, perceived level of fatigue and associated discomfort (using three items from the Piper Fatigue Scale [6] ) and health-related quality of life (HRQL) (using the Medical Outcomes Study (MOS) SF-12 scale [7] ). These PROs were evaluated at follow-up visits at day 0, week 12 and week 24 for noncirrhotic patients and day 0, week 12, week 24 and week 36 for cirrhotic patients.
Pharmacokinetics
Twenty subjects receiving an antiretroviral treatment consisting of the combination of tenofovir, emtricitabine and raltegravir were enrolled in an intensive 10-h pharmacokinetics (PK) substudy. PK profiles were obtained at hours 0, 1, 2, 3, 6, 8 and 10. Plasma samples from these patients were analysed for antiretroviral drug concentrations at day 0 and week 4 (liquid chromatography coupled with tandem mass spectrometry; Medical Pharmacology and Toxicology Unit, Pasteur University Hospital, Nice, France). Quantification limits were 10 lg/L for tenofovir and 25 lg/L for raltegravir. SOF, GS-331007 (the predominant circulating metabolite of SOF) and LDV concentrations were analysed at week 4 (Gilead Sciences, Inc.).
Statistical analysis
Qualitative data are presented as number and percentage and quantitative data are presented as median and IQR or mean and standard deviation (SD), as appropriate.
The primary efficacy endpoint was the SVR12 rate measured at week 36 for cirrhotic patients and week 24 for noncirrhotic patients. For analysis of the main endpoint, an intention-to-treat (ITT) analysis was performed with a test comparing an observed to a theoretical proportion using a unilateral formulation with a type I error of 5%. The rate of SVR12 below which the therapy would be considered inefficient was fixed at 50% (null hypothesis). The rate of SVR12 above which the therapy would bring a real benefit was fixed at 70% (alternative hypothesis). To guarantee 95% power to detect such a 20% benefit, and considering the statistical hypotheses, a minimum of 39 (out of 64) participants with an SVR12 were required to conclude that the SVR rate was > 50%.
The time needed to obtain HCV undetectability was compared between noncirrhotic and cirrhotic patients using a log rank test with a significance level of P < 0.05. The evolution of pharmacokinetic parameters (week 0-4) was compared with a paired Wilcoxon test.
The number of patients with adverse events in the noncirrhotic group was compared with that in the cirrhotic group using a v 2 test or Fisher's exact test with a significance level of P < 0.05. Changes in PROs with time were analysed using mixed linear and logistic regression models (for continuous and binary outcomes, respectively). Variables tested in the models included time, gender, age and cirrhosis status as potential modifiers of PROs. All tests were two-sided, with a significance level a fixed at 0.05. SAS 
Results
Study patients
A total of 74 patients from 30 participating centres were screened for enrolment between August 2014 and March 2015. Six patients were not enrolled for the following reasons: cirrhosis Child-Pugh B (one patient), liver biopsy refused by the patient although needed for cirrhosis status documentation (one patient), MDRD creatinine clearance < 60 mL/min (two patients), haematological exploration being performed (one patient) and HIV treatment regimen including dolutegravir (one patient). Sixty-eight patients were enrolled and started the treatment. Demographic characteristics of these 68 patients at baseline are presented in Table 1 . Among the 27 patients with cirrhosis, the median baseline albumin level was 40 g/dL, the median platelet count was 132 G/L and the median international normalized ratio was 1.1.
Efficacy
Among the 68 patients who were enrolled and treated, 65 [95.6%; 95% confidence interval (CI): 87.6-99.1%; P < 0.0001] had an SVR12 and SVR24 (Fig. 1) . Despite achieving SVR12 and SVR24, three patients were regarded as having treatment failure: one noncirrhotic patient had never been exposed to HCV PIs, and so deviated from the inclusion criteria; one patient with cirrhosis prematurely discontinued study drugs at week 2, as planned in the protocol, for gastrointestinal bleeding needing proton-pump inhibitor treatment, and secondarily started the treatment again; and nonscheduled ribavirin was introduced at week 12 in one patient with cirrhosis for persistently detectable HCV RNA. Regarding HCV kinetics, although not significant, our data suggest a trend for more rapidly undetectable HCV viral load in noncirrhotic patients compared with patients with cirrhosis (Fig. S1 ).
Safety
One of the 68 patients in the study discontinued the treatment prematurely, as planned in the protocol, because of gastrointestinal bleeding needing a proton-pump inhibitor treatment, which is known to interact with LDV. All the patients (100%) presented at least one adverse event; most of them were mild to moderate in severity (Table 2) . Eleven patients had serious adverse events, including thrombocytopaenia in one patient, considered to be drugrelated by the investigator. Study investigators reported mild proteinuria, hypophosphataemia, blood bicarbonate decrease and hypokalaemia in 54.4%, 50.0%, 29.4% and 13.2% of patients, respectively. They reported blood bicarbonate decrease more frequently in patients with cirrhosis than in noncirrhotic patients (44.4% vs. 19.5%, respectively; P = 0.03). In contrast, no change in serum creatinine clearance level (Fig. S2 ), blood bicarbonate, SD, standard deviation; HCV, hepatitis C virus; IQR, interquartile range; PI, protease inhibitor; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine. *Two patients had HIV RNA < the lower limit of quantification (LLOQ) of 80 copies/mL at baseline.
Non-cirrhotic patients (n = 41) Cirrhotic patients (n = 27) phosphate, potassium or urinary protein was noted in the whole population (data not shown), and no quantitative change in creatinine level, blood bicarbonate, phosphate or potassium was noted during the study duration among patients with investigator-reported renal events (Figs S3-S6). CD4 cell counts were stable throughout treatment and the follow-up phase. One patient had a confirmed HIV virological rebound post discontinuation of antiretroviral treatment at week 28. A second patient displayed a confirmed low-level HIV RNA rebound at week 12 (73 copies/mL) with undetectability obtained after anti-HIV treatment modification.
Patient-reported outcomes
Patients showed high levels of adherence to both antiretroviral and HCV treatments during follow-up (Table 3 ). The median (IQR) number of self-reported symptoms was 5 (2, 9) at week 0 and remained relatively stable during followup. Figure 2 presents the type of symptoms reported at the end of HCV treatment (EOT) for noncirrhotic and cirrhotic patients. In the univariable analyses, female gender and the presence of cirrhosis were significantly associated with a higher number of self-reported symptoms causing discomfort and poorer physical quality of life. After adjustment for study visit (week 0, EOT and SVR12), the presence of cirrhosis was independently associated with a higher number of self-reported symptoms causing discomfort during followup (model coefficient 1.61; 95% CI: 0.27, 2.96; P = 0.02), poorer physical HRQL (model coefficient À6.94; 95% CI: À10.81, À3.07; P < 0.001) and greater fatigue (model coefficient 1.14; 95% CI: 0.13, 2.14; P = 0.03). No significant change with time was observed for the different PROs analysed, except for the discomfort associated with fatigue, which significantly decreased compared with week 0 both at EOT [odds ratio (OR): 0.36; 95% CI: 0.14, 0.96; P = 0.04] and 12 weeks later (OR: 0.35; 95% CI: 0.13, 0.95; P = 0.04).
Pharmacokinetics
PK parameters evaluated for LDV, SOF, GS-331007, tenofovir and raltegravir are presented in Table 4 . AUC24 values for tenofovir and raltegravir were not different in cirrhotic and noncirrhotic patients (Table S1 ), neither at baseline nor *Listed are adverse events that were reported in at least 10% of patients. Patients could have more than one adverse event or serious adverse event. at week 4. In contrast, for tenofovir, the AUC variation between baseline and week 4 was significantly higher in patients with cirrhosis than in noncirrhotic patients, with a mean (AESD) difference of 3261.57 AE 1920.47 and 1576.15 AE 911.97 ng/mL (P = 0.03) in cirrhotic and noncirrhotic patients, respectively. No association was found between tenofovir exposure and reporting of mild proteinuria, hypophosphataemia, blood bicarbonate decrease or hypokalaemia by the investigators.
Discussion
In this nonrandomized, double-arm, open-label phase II pilot trial, the combination of LDV and SOF was associated with high rates of SVR in participants coinfected with HCV genotype 1 and HIV, independent of the presence of cirrhosis. The participants included in this study had many factors previously described as being associated with a poor prognosis, including male sex (79.4%), genotype 1a infection (82.4%) and cirrhosis (39.7%). All the patients had previously been exposed to triple therapy with peginterferon/ribavirin and a PI, and 59.3% of patients with cirrhosis had previously received more than three treatment courses for HCV infection. Previous studies showed that LDV/SOF for 12 weeks without ribavirin provided high rates of SVR in patients with HCV genotype 1, including (1) those coinfected with HIV-1, (2) those with previous treatment failure while receiving regimens that included DAA drugs, and (3) those with cirrhosis [2, 8] . In our study, 24 weeks' duration of LDV/SOF was chosen to maximize the SVR rate in heavily pretreated patients with cirrhosis, and allowed patients to achieve high rates of SVR. Viral efficacy of 12 weeks' duration of therapy with LDV/SOF without ribavirin in the cirrhotic patients enrolled in our study cannot be predicted. As previously shown for HCV genotype 3 [9] , our data suggest that patients with cirrhosis had a slower virological response as compared with noncirrhotic patients. Several studies indicated that residual viraemia during highly effective interferon (IFN)-free combination therapy was not predictive of virological failure [9] [10] [11] . In contrast, a recent publication suggested that use of early viral kinetic analysis has the potential to individualize the duration of DAA agent therapy [12] . Both an integrated analysis of 513 patients and the results of the SIRIUS study showed that LDV/SOF for 24 weeks and LDV/SOF plus ribavirin for 12 weeks provided similarly high SVR rates in previous nonresponders with HCV genotype 1 and compensated cirrhosis, LDV/ SOF without ribavirin for 12 weeks demonstrating lower SVR rates in these patients [13, 14] . Based on these data, both American and European guidelines recommend 24 weeks of the fixed-dose combination of LDV/SOF without ribavirin, or alternatively 12 weeks of the same combination with ribavirin, in treatment-experienced patients with compensated (Child-Pugh A) cirrhosis who failed to achieve an SVR, including patients having received treatment with pegylated IFN-a, ribavirin and either telaprevir or boceprevir [15, 16] . In HIV-coinfected patients, the ION-4 study showed that LDV/SOF for 12 weeks showed high SVR rates, including in treatment-experienced subjects and those with compensated cirrhosis. Studies from real life investigating all-oral DAA regimens in people coinfected with HIV/HCV, in particular results from the prospective ANRS CO-13-HEPAVIH cohort study [17] , showed no difference between 12 and 24 weeks' DAA treatment durations or between regimens with and without ribavirin. However, in this observational study, the allocation of different regimens was not based on a predefined protocol but depended on physician choice. Consequently, % CV, coefficient of variablility; AUC, area under the plasma concentration-time curve during the dosing interval; C max , maximum concentration; RS, Wilcoxon signed rank test: C tau : concentration at the end of the dosing interval. *One patient was excluded from PK analysis based upon the subject's dosing record, which showed that the PK substudy dose of LDV/SOF was administered approximately 8 h after the previous dose of LDV/SOF.
comparison regarding treatment duration or the use of ribavirin could not be performed. Our results provide further data in HIV-coinfected patients and support the administration of LDV/SOF for 24 weeks in treatment-experienced patients with compensated cirrhosis. In this study, most adverse events associated with combined LDV/SOF were mild (grade 1-2) and clinically managed. There were no deaths or medication discontinuations attributable to the study drug. Previous studies showed that, compared with HCV-monoinfected patients, HIV/HCV-coinfected patients from the PHOTON 1 and 2 studies had more impairment of PROs prior to the initiation of treatment [18] . In addition, compensated cirrhosis negatively impact PROs in patients with chronic hepatitis C [19] . In our study, a higher number of self-reported symptoms were also observed, and, as previously reported in HIV/HCV-coinfected patients [20] , the individuals included in the SOFTRIH trial showed significant improvement for discomfort associated with fatigue, which significantly decreased during treatment and after treatment cessation. This may account for the high level of adherence to HCV treatment observed in our study.
LDV/SOF has limited potential for clinically significant drug interactions with most antiretroviral agents [21, 22] . However, results from phase 1 evaluations showed that concomitant administration of LDV/SOF and tenofovir disoproxil fumarate as a component of an antiretroviral regimen resulted in a modest increase (approximately 40%) in the exposure to tenofovir, as compared with an antiretroviral regimen alone [21, 22] . In our study, LDV, SOF and GS-331007 exposures were generally within the ranges (minimum to maximum) of exposures observed in the populations of LDV/SOF phase 2/3 studies (Gilead, personal communication). In contrast, in this trial, administration of emtricitabine plus tenofovir disoproxil fumarate with LDV/SOF in patients coinfected with HCV and HIV-1 resulted in a 50% higher tenofovir exposure than previously reported with antiretroviral regimens alone [21] , especially in patients with cirrhosis. In addition, the overexposure to tenofovir was slightly higher than that reported in the LDV/SOF package insert [21] . Our study showed no significant change in creatinine clearance, nor any relationship between tenofovir exposure and renal proximal tubulopathy reported signs. It is not unlikely that more systematic intensive renal monitoring might have revealed treatment-emergent proximal tubule dysfunction. In the ION-4 study, 5.67% of patients had a creatinine clearance decrease > 25% and 34.0% had an incident increase in urine proteinuria from negative/trace to ≥ 1 during LDV/SOF treatment. In these patients, baseline levels of retinol-binding protein-4, a urinary biomarker of proximal tubule dysfunction, were higher for patients with incident proteinuria (P < 0.001) and increased from baseline to EOT [23] . There was a positive correlation with tenofovir exposure, and the authors proposed dosing of retinolbinding protein-4 to identify patients at risk of tubular toxicity who have increased exposures to tenofovir.
Limitations of this study include its noncomparative open-label design and the restriction of permitted antiretroviral regimens. In addition, use of ritonavirboosted HIV-1 PIs or cobicistat-boosted elvitegravir with tenofovir disoproxil fumarate was not permitted in our study because of the potential for additional increases in tenofovir exposure. The potential effects of these antiretroviral treatments combined with LDV/SOF therapy on renal function should be addressed in future studies.
In conclusion, we found that a fixed-dose combination of LDV/SOF provided high rates of SVR in subjects with HCV genotype 1 who were coinfected with HIV-1 and with previous treatment failure on or intolerance to triple therapy with peg-interferon/ribavirin and a PI. While 12 weeks' treatment duration is highly effective in noncirrhotic patients, 24 weeks' duration of LDV/SOF may be better in heavily pretreated cirrhotic patients to achieve the highest SVR rates, as recommended in recent guidelines [15, 16] . 
